According to the latest report by IMARC Group, titled “Tissue Diagnostics Market Report by Product Type (Instruments, Consumables), Technology (Immunohistochemistry, In Situ Hybridization, Digital Pathology and Workflow Management, Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, and Others), End-User (Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations, and Others), and Region 2024-2032”, the global tissue diagnostics market reached a value of US$ 5.5 Billion in 2023. Tissue diagnostics has been practiced across the globe for over a century. It is the process of staining and removing tissues for diagnosing a disease, and is mostly employed in oncology. The procedure is used for recognizing specific antigens that are present in preserved tissues. It consists of slicing thin tissue samples, which are treated with a stain of hematoxylin and eosin (H&E). These samples are then formalin-fixed paraffin-embedded (FFPE) in order to identify tumors and other specimens of histopathology. Tissue diagnostics help in detecting the existence of cancer and analyzing other features that may assist in making disease management decisions.
Global Tissue Diagnostics Market Trends:
With the emergence of network-based medicine, there has been a rise in the requirement of improvements across all facets of healthcare to enhance the detection, visualization and monitoring of diseases. Owing to this, several innovations have been made in the automation of novel platforms and staining equipment, such as digital immunohistochemistry (IHC), which is expected to play a vital role as an advanced laboratory information system (LIS). Besides this, the rising incidences of cancer have prompted governmental and non-governmental organizations across the globe to take initiatives for spreading awareness about the causes, prevention, diagnosis and treatment of cancer. For instance, in September 2018, WHO introduced the WHO Global Initiative for Childhood Cancer, which aims to reach nearly 60% survival rate for children with cancer. Such campaigns are creating a need for high-quality diagnostic services across both the developed and developing regions. Looking forward, the market is projected to reach a value of US$ 9.4 Billion by 2032, registering a CAGR of 5.9% during 2024-2032.
Market Summary:
- The market has been bifurcated based on the product type, wherein consumables account for the majority of the market share.
- On the basis of the technology, the market has been segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow management, and special staining. Among these, immunohistochemistry represents the most preferred technology segment.
- The market has been segregated according to the disease, which includes breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and others. At present, tissue diagnostics is mostly employed for diagnosing breast cancer.
- Based on the end user, the market has been categorized as hospitals, research laboratories, pharmaceutical companies, contract research organizations, and others. Hospitals currently exhibit a clear dominance in the market.
- On a regional basis, North America is the leading market and holds the largest market share. Other regions include Europe, Asia Pacific, Middle East and Africa, and Latin America.
- The competitive landscape of the market has also been examined with some of the key players being Roche, Danaher, Thermo Fisher Scientific, Abbott, Agilent Technologies, Merck, Sakura Finetek Japan, Abcam, BD, Qiagen, Bio SB, Biogenex, and Cell Signaling Technology.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Product Type, Technology, Disease, End-User, Region |
Region Covered |
North America, Europe, Asia Pacific, Middle East and Africa, Latin America |
Companies Covered |
Roche, Danaher, Thermo Fisher Scientific, Abbott, Agilent Technologies, Merck, Sakura Finetek Japan, Abcam, BD, Qiagen, Bio SB, Biogenex and Cell Signaling Technology |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal